Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial
Francesca Lombardi(Università Cattolica del Sacro Cuore), Gabriella d’Ettorre(Policlinico Umberto I), Roberto Cauda(Università Cattolica del Sacro Cuore), Andrea De Luca(Agostino Gemelli University Polyclinic), Massimiliano Fabbiani(University of Siena), Eugenia Quirós-Roldán(Karolinska Institutet), Alessandra Latini(San Gallicano Hospital), Antonella Castagna(Vita-Salute San Raffaele University), Simone Belmonti(Università Cattolica del Sacro Cuore), Roberta Gagliardini(Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani), Simona Di Giambenedetto(Università Cattolica del Sacro Cuore)
Cited by 31
Related Papers
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review
|International Journal of Environmental Research and Public Health|2021|272
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study
|Clinical Infectious Diseases|2021|264
Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels
|medRxiv|2020|234
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency
|Critical Care and Resuscitation|2020|229